AJANTPHARM.NS Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 май 2024 @ 13:00):

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets finished dosages...

Stats
Объем за сегодня	364 632
Средний объем	161 866
Рыночная капитализация	304.03B
EPS	INR0 ( 2024-05-01 )
Дата следующего отчета о доходах	( INR23.80 ) 2024-07-24
Last Dividend	INR15.00 ( 2023-08-04 )
Next Dividend	INR0 ( N/A )
P/E	41.44
ATR14	INR2.32 (0.10%)

Объем Корреляция

Длинно: -0.01 (neutral)

Кратко: -0.26 (neutral)

Signal:(52.563) Neutral

Ajanta Pharma Limited Корреляция

10 Самые положительные корреляции
BHARATWIRE.NS	0.837
IZMO.NS	0.823
ASHIANA.NS	0.821
ASIANHOTNR.NS	0.805
AUROPHARMA.NS	0.801
GISOLUTION.NS	0.801

10 Самые отрицательные корреляции
STARTECK.NS	-0.829
SEYAIND.NS	-0.806

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Ajanta Pharma Limited Корреляция - Валюта/Сырье

0.17
( neutral )

0.03
( neutral )

0.07
( neutral )

0.53
( weak )

-0.13
( neutral )

Ajanta Pharma Limited Финансовые показатели

Annual	2023
Выручка:	INR42.09B
Валовая прибыль:	INR21.06B (50.05 %)
EPS:	INR64.82

FY	2023
Выручка:	INR42.09B
Валовая прибыль:	INR21.06B (50.05 %)
EPS:	INR64.82

FY	2022
Выручка:	INR37.43B
Валовая прибыль:	INR26.92B (71.93 %)
EPS:	INR45.89

FY	2022
Выручка:	INR32.84B
Валовая прибыль:	INR23.97B (73.00 %)
EPS:	INR54.97

Financial Reports:

No articles found.

Ajanta Pharma Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR7.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR15.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Ajanta Pharma Limited Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.30 - Stable (6.10%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.133	2002-12-17
Last Dividend	INR15.00	2023-08-04
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	20	--
Total Paid Out	INR73.42	--
Avg. Dividend % Per Year	0.57%	--
Score	3.24	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.30
Div. Directional Score	7.71	--

Next Divdend (Est)
(2024-08-29)

INR16.81 Estimate 3.06 %

Dividend Stability

0.24 Very Poor

Dividend Score

3.24

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR6.00	0.78%
2019	INR8.67	1.10%
2020	INR6.33	0.97%
2021	INR6.33	0.58%
2022	INR7.00	0.47%
2023	INR15.00	1.24%
2024	INR0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
RBLBANK.NS	Dividend Junior	2023-08-18	Sporadic	8	0.25%
KOVAI.NS	Dividend Junior	2023-08-10	Annually	4	0.17%
EXIDEIND.NS	Dividend Junior	2023-08-01	Annually	22	0.76%
AMIORG.NS	Dividend Junior	2023-09-18	Annually	3	0.15%
TALBROAUTO.NS	Dividend Junior	2023-09-15	Annually	18	0.48%
NGIL.NS	No Dividend Player	2023-09-21	Annually	4	0.08%
IGPL.NS	Dividend Junior	2023-08-17	Sporadic	18	1.12%
CHEMFAB.NS	Dividend Junior	2023-08-22	Sporadic	7	0.32%
SAKSOFT.NS	Dividend Junior	2023-08-07	Semi-Annually	20	0.56%
LUMAXIND.NS	Dividend Junior	2023-08-10	Annually	23	1.26%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.194	1.500	6.12	9.18	[0 - 0.5]
returnOnAssetsTTM	0.176	1.200	4.13	4.96	[0 - 0.3]
returnOnEquityTTM	0.235	1.500	8.51	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.05	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	1.944	0.800	3.27	2.62	[0.8 - 2.5]
cashRatioTTM	0.146	1.500	-0.300	-0.450	[0.2 - 2]
debtRatioTTM	0.00761	-1.500	9.87	-10.00	[0 - 0.6]
interestCoverageTTM	147.56	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	16.08	2.00	4.64	9.28	[0 - 30]
freeCashFlowPerShareTTM	16.08	2.00	1.958	3.92	[0 - 20]
debtEquityRatioTTM	0.00989	-1.500	9.96	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.683	1.000	1.951	1.951	[0.2 - 0.8]
operatingProfitMarginTTM	0.253	1.000	6.94	6.94	[0.1 - 0.6]
cashFlowToDebtRatioTTM	5.74	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.907	0.800	7.28	5.83	[0.5 - 2]
Total Score				10.12

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	35.96	1.000	6.47	0	[1 - 100]
returnOnEquityTTM	0.235	2.50	9.04	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	16.08	2.00	4.64	3.92	[0 - 30]
dividendYielPercentageTTM	1.759	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	16.08	2.00	4.64	9.28	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	1.068	1.500	6.22	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0481	1.000	-1.297	0	[0.1 - 0.5]
Total Score				5.30

Ajanta Pharma Limited

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets finished dosages. The company markets and serves various therapeutic segments, such as anti-biotic, anti-malarial, anti-diabetic, cardiology, gynecology, pediatric, respiratory and general health products, dermatology, ophthalmology, and pain management areas. It also provides multivitamins, antibiotics, eye drops, cough syrups, etc. The company serves in India, Africa, rest of Asia, the United States, and internationally. It supplies its products to government bodies, including armed forces, government hospitals, canteens, stores department, etc. The company was founded in 1973 and is headquartered in Mumbai, India.